Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
PROCEPT BioRobotics Corporation Market Cap
From what 8 stock analysts predict, the share price for PROCEPT BioRobotics Corporation (PRCT) might increase by 10.6% in the next year. This is based on a 12-month average estimation for PRCT. Price targets go from $95 to $105. The majority of stock analysts believe PRCT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 8 Wall Street analysts have assigned PRCT 6 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect PROCEPT BioRobotics Corporation to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PRCT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PRCT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Sarcone Jefferies | Hold | $95 | Initiates | Nov 14, 2024 |
| Richard Newitter Truist Securities | Buy | $105 | Reiterates | Oct 30, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $75 | Reiterates | Oct 8, 2024 |
| Joshua Jennings TD Cowen | Buy | $99 | Maintains | Sep 16, 2024 |
| Richard Newitter Truist Securities | Buy | $95 | Maintains | Sep 3, 2024 |
| Craig Bijou B of A Securities | Buy | $94 | Maintains | Aug 22, 2024 |
| Nathan Treybeck Wells Fargo | Overweight | $69 | Maintains | Aug 2, 2024 |
| Richard Newitter Truist Securities | Buy | $74 | Reiterates | Aug 2, 2024 |
| Richard Newitter Truist Securities | Buy | $79 | Maintains | Jul 16, 2024 |
| Matt O'Brien Piper Sandler | Overweight | $75 | Maintains | May 6, 2024 |
| Joshua Jennings TD Cowen | Buy | $75 | Maintains | May 6, 2024 |
| Richard Newitter Truist Securities | Buy | $72 | Maintains | May 2, 2024 |
| Richard Newitter Truist Securities | Buy | $58 | Maintains | Feb 28, 2024 |
| Nathan Treybeck Wells Fargo | Overweight | $47 | Maintains | Jan 9, 2024 |
| Richard Newitter Truist Securities | Buy | $50 | Maintains | Dec 22, 2023 |
| Nathan Treybeck Wells Fargo | Overweight | $44 | Maintains | Dec 13, 2023 |
| Mike Kratky Leerink Partners | Outperform | $37 | Initiates | Oct 16, 2023 |
| Richard Newitter Truist Securities | Buy | $49 | Reiterates | Sep 13, 2023 |
| Matt O'Brien Piper Sandler | Overweight | $42 | Initiates | Aug 11, 2023 |
| Brandon Vazquez William Blair | Outperform | Initiates | May 31, 2023 |
When did it IPO
2021
Staff Count
626
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Reza Zadno Ph.D.
Market Cap
$5.26B
In 2023, PRCT generated $136.2M in revenue, which was a increase of 81.55% from the previous year. This can be seen as a signal that PRCT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PROCEPT BioRobotics (Nasdaq: PRCT) will present at the 36th Annual Piper Sandler Healthcare Conference on December 4 at 8:30 a.m. ET in New York City.
Why It Matters - Management presentations at major conferences can influence investor sentiment, potentially impacting stock performance and providing insights into company strategy and growth prospects.
Tue, 26 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - PRCT reported Q3 sales growth of 66% YoY and record gross margins of 63%. Management projects $223M in sales for the year, with a 64% growth forecast. The model supports recurring revenue.
Why It Matters - Strong sales growth and high gross margins indicate robust financial health. The forecasted growth and recurring revenue model suggest potential for sustained profitability, attracting investor interest.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - PROCEPT BioRobotics Corporation (PRCT) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters - The inquiry into PRCT's potential as a top stock pick signals interest in its growth prospects, which may influence market sentiment and trading activity among momentum investors.
Mon, 28 Oct 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - PROCEPT BioRobotics (PRCT) stock is trading positively following the release of better-than-expected third-quarter earnings.
Why It Matters - Better-than-expected earnings can boost investor confidence, potentially increasing PRCT stock value and attracting more buyers, which may lead to a favorable market perception.
Mon, 28 Oct 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Procept Biorobotics shares rose after the company exceeded September-quarter expectations and raised its outlook.
Why It Matters - Procept Biorobotics' strong earnings and improved outlook indicate robust growth potential, likely boosting investor confidence and driving share prices higher.
Mon, 28 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - PROCEPT BioRobotics will hold its Q3 2024 earnings conference call on October 28, 2024, at 8:00 AM ET, featuring key executives and financial analysts from various firms.
Why It Matters - Earnings conference calls provide insights into a company's performance and future outlook, influencing investor sentiment and stock valuation. Key executives’ commentary can impact stock movement.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
